List of Excipients in Branded Drug DECITABINE

« Back to Dashboard

Generic Drugs Containing DECITABINE

Company	Ingredient	NDC	Excipient
Hikma Pharmaceuticals USA Inc	decitabine	0143-9385	HYDROCHLORIC ACID
Hikma Pharmaceuticals USA Inc	decitabine	0143-9385	POTASSIUM PHOSPHATE, MONOBASIC
Hikma Pharmaceuticals USA Inc	decitabine	0143-9385	SODIUM HYDROXIDE

What are the Most Frequently-Used Excipients in DECITABINE?

# Of NDCs	Excipient
10	HYDROCHLORIC ACID
5	MONOBASIC POTASSIUM PHOSPHATE
1	NITROGEN

Decitabine Excipient Strategy and Commercial Opportunities

Last updated: October 21, 2026

Decitabine has two commercially relevant dosage forms: intravenous decitabine, marketed as Dacogen and generic equivalents, and the oral fixed-dose combination decitabine/cedazuridine, marketed as Inqovi. The largest formulation opportunities are linked to decitabine’s chemical instability in aqueous solution, the operational burden of intravenous administration, and the need to preserve oral exposure without relying on complex excipient systems.

What excipients are used in decitabine products?

The approved products use relatively simple excipient systems. Their commercial value comes from controlling stability, reconstitution, tablet performance, and exposure rather than from highly differentiated inactive ingredients.

Product	Active ingredients	Dosage form	Key excipients or formulation attributes	Commercial implication
Dacogen	Decitabine 50 mg	Lyophilized intravenous powder	Potassium phosphate monobasic and sodium hydroxide; reconstituted and diluted before infusion	Low excipient complexity but high handling burden
Generic decitabine injection	Decitabine	Lyophilized intravenous powder	Generally similar pH-control and bulking strategy, subject to approved formulation	Manufacturing efficiency and in-use stability are primary differentiators
Inqovi	Decitabine 35 mg plus cedazuridine 100 mg	Oral film-coated tablet	Mannitol, croscarmellose sodium, magnesium stearate, and film-coating components	Oral convenience and fixed-dose combination drive product value
Future oral decitabine products	Decitabine alone or in combination	Tablet, capsule, multiparticulate, or modified-release system	Potentially includes permeability, pH-modifying, protective, or controlled-release excipients	Opportunity depends on exposure, bioavailability, and patent differentiation

Dacogen contains potassium phosphate monobasic and sodium hydroxide as inactive ingredients. The formulation is supplied as a sterile lyophilized powder because decitabine is susceptible to degradation after reconstitution. The product is reconstituted with sterile water and further diluted before intravenous infusion. The labeled product requires controlled handling and limited storage time after preparation. [1]

Inqovi uses a conventional oral solid-dose platform. The tablet contains decitabine and cedazuridine, a cytidine deaminase inhibitor that increases systemic exposure to orally administered decitabine. The product’s excipients support tablet compression, disintegration, lubrication, and film coating. [2]

Why is decitabine formulation technically difficult?

Decitabine is a cytidine analog with limited stability in aqueous environments. Hydrolytic degradation can reduce potency and complicate manufacturing, reconstitution, storage, and administration.

The central formulation constraints are:

1. Protection from aqueous degradation.
2. Control of pH during manufacture and reconstitution.
3. Maintenance of dose uniformity at low drug loading.
4. Preservation of chemical integrity during sterilization and filling.
5. Management of short post-reconstitution and post-dilution handling windows.
6. Reliable oral absorption when decitabine is administered without cedazuridine.

Aqueous ready-to-use products face the highest stability burden. Lyophilization reduces water activity and permits a commercially practical shelf life, but it increases manufacturing cost and requires reconstitution at the treatment site.

A formulation that extends in-use stability could reduce waste, improve pharmacy workflow, and support outpatient administration. The opportunity is commercially meaningful because decitabine is commonly used in repeated treatment cycles, making preparation time and vial waste recurring cost drivers.

What excipient strategies are most relevant to intravenous decitabine?

pH control

Phosphate buffering and sodium hydroxide adjustment provide a relatively simple route to control formulation pH. A development program could evaluate alternative buffer systems, including citrate or histidine, but any replacement must preserve:

• Decitabine chemical stability.
• Lyophilized cake quality.
• Reconstitution time.
• Compatibility with infusion materials.
• Sterility assurance.
• Tolerability after intravenous administration.

A buffer change alone may be difficult to protect broadly unless it produces a measurable stability, safety, or administration advantage.

Lyophilization optimization

The strongest near-term opportunity is not necessarily a new excipient. It may be an improved lyophilization cycle using existing pharmaceutical-grade excipients or a revised solid-state system.

Relevant development variables include:

• Collapse temperature.
• Residual moisture.
• Cake structure.
• Reconstitution time.
• Vial-to-vial dose uniformity.
• Long-term degradation products.
• Resistance to transport excursions.

Mannitol, trehalose, sucrose, and selected polymeric bulking agents are potential development candidates, although each introduces tradeoffs in cake structure, moisture sensitivity, reconstitution, and regulatory precedent.

Ready-to-use liquid presentations

A ready-to-use liquid decitabine product could eliminate reconstitution and reduce pharmacy labor. The technical barrier is chemical stability. Commercially viable approaches could include:

• Low-water or nonaqueous systems.
• Dual-chamber containers.
• On-demand reconstitution devices.
• Frozen or refrigerated presentations.
• Stabilized concentrated solutions.
• Container systems that limit oxygen, moisture, or light exposure.

These approaches would compete against the simplicity and low regulatory risk of a conventional lyophilized vial. Their value would need to exceed additional packaging, cold-chain, and manufacturing costs.

Container-closure systems

Packaging can be part of the formulation strategy. Low-permeability vials, improved elastomeric stoppers, oxygen-reducing headspace control, and unit-dose packaging may extend stability without changing the active formulation.

A packaging-led product may have a lower clinical development burden than a new route of administration, but its patent scope can be narrower. Regulatory approval would still require data showing that the container does not introduce extractables, leachables, adsorption, or particulate risks.

What excipient strategies are relevant to oral decitabine?

Oral decitabine has two separate barriers: chemical degradation in the gastrointestinal tract and extensive metabolism by cytidine deaminase. Inqovi addresses the second barrier with cedazuridine. An excipient strategy alone may not reproduce the exposure profile of the approved combination.

Direct-compression tablet systems

The Inqovi platform uses conventional tablet excipients. A generic or follow-on product could target:

• Improved tablet hardness.
• Faster disintegration.
• Lower tablet mass.
• Better moisture protection.
• Reduced manufacturing compression force.
• Improved content uniformity.
• Alternative film-coating systems.

These changes can improve manufacturing economics but may provide limited market differentiation unless they support a distinct product claim.

Protective coating and enteric systems

An enteric or delayed-release system could seek to protect decitabine from gastric degradation or release drug at a site with more favorable absorption. The risks include delayed or incomplete exposure, food effects, and variability among patients receiving intensive hematology treatment.

An enteric coating is more commercially attractive if it produces a reproducible pharmacokinetic benefit without requiring cedazuridine. That would require comparative clinical evidence and may create a new patent position around release location, composition, or pharmacokinetic performance.

Permeation and absorption enhancers

Lipid-based systems, surfactants, mucoadhesive polymers, and permeation enhancers could increase oral absorption. Their use is constrained by:

• Gastrointestinal tolerability.
• Dose proportionality.
• Interaction with other oral medicines.
• Manufacturing complexity.
• Variable absorption in patients with mucositis or gastrointestinal disease.
• Regulatory scrutiny of chronic or repeated exposure.

In hematologic oncology, tolerability and predictable exposure are more important than maximum absorption alone.

Amorphous solid dispersions and particle engineering

Amorphous dispersions, nanosizing, co-crystals, and spray-dried systems could improve dissolution. These approaches are more relevant if dissolution, rather than deamination, is the dominant barrier in a particular product design.

Because cedazuridine directly addresses enzymatic degradation, a formulation-only product must show a clear advantage over the approved combination. A smaller tablet, lower dose, improved food independence, or reduced treatment burden could support a commercially differentiated product.

What commercial opportunities exist for decitabine excipients?

Generic intravenous decitabine

The most accessible opportunity is generic or contract-manufactured intravenous decitabine. The product has a known clinical use, a relatively simple qualitative formulation, and recurring hospital demand.

Commercial success depends on:

• Reliable sterile manufacturing.
• Competitive vial pricing.
• Low batch-failure rates.
• Short preparation times.
• Adequate supply during oncology-treatment cycles.
• Demonstrated stability after reconstitution.
• Efficient packaging and distribution.

A differentiated generic could offer longer in-use stability, fewer preparation steps, or a more efficient vial size. These benefits may support hospital formulary adoption even without a new route of administration.

Ready-to-administer products

A ready-to-administer decitabine product could target hospital pharmacies, ambulatory infusion centers, and specialty oncology networks. The value proposition would be lower pharmacy labor, reduced preparation errors, and less product waste.

The principal commercial challenge is cost. A more complex presentation may be rejected if the price premium exceeds the pharmacy savings.

Oral decitabine alternatives

The oral market is more difficult because Inqovi combines decitabine with cedazuridine. An oral decitabine product without cedazuridine would need to overcome first-pass metabolism through formulation, dose design, or a different delivery system.

Potential commercial positions include:

• Lower pill burden.
• Reduced tablet size.
• Improved gastrointestinal tolerability.
• More predictable exposure.
• Flexible dosing for outpatient treatment.
• Lower cost than the branded fixed-dose combination.
• Compatibility with combination regimens.

Pediatric and geriatric formulations

Age-appropriate formulations could support smaller patient populations, particularly dispersible tablets, oral granules, or liquid systems. The product must maintain stability at low concentrations and support accurate dose measurement.

A pediatric formulation would require more than a different flavoring system. Dose uniformity, administration-device compatibility, and stability after opening would be central regulatory issues.

Combination products

Decitabine is used in combination with other hematology therapies, including venetoclax in clinical practice. Co-packaged products, coordinated dosing kits, and fixed-dose combinations could reduce treatment complexity. A formulation company could pursue co-packaging or dose-calendar solutions without changing the decitabine molecule.

A fixed-dose combination would face substantial development and intellectual-property requirements because dose flexibility is clinically important in myelodysplastic syndromes and acute myeloid leukemia.

What patents protect decitabine formulations?

Decitabine’s basic compound and original intravenous product protections are mature. The principal current opportunities are more likely to involve:

• Oral decitabine and cedazuridine combinations.
• Specific dose ratios.
• Treatment schedules.
• Pharmacokinetic exposure.
• Formulation stability.
• Modified-release systems.
• Manufacturing and purification processes.
• Container-closure and ready-to-use presentations.

The original Dacogen product is an intravenous formulation approved in the United States in 2006. Compound-level and core product protection for decitabine has largely expired or reached the end of its commercial life. The relevant remaining barriers are product-specific patents, regulatory exclusivities, manufacturing know-how, and clinical differentiation. [1,3]

Inqovi received FDA approval in July 2020. Its commercial protection is tied to the decitabine/cedazuridine combination, approved dosing regimen, clinical use, and associated patent rights. The FDA Orange Book should be reviewed for current listed patents and any updates to patent certifications or exclusivity status. [2,4]

How strong is the formulation patent estate?

The formulation estate is strongest when it links composition to a measurable technical result, such as:

• A defined impurity profile.
• Extended stability at a specified temperature.
• Reconstitution within a defined time.
• Improved oral bioavailability.
• Reduced food effect.
• A specific dissolution profile.
• A pharmacokinetic exposure range.
• Reduced dosing frequency.

Weak claims usually cover conventional excipients at broad concentration ranges without a demonstrated technical effect. Stronger claims combine composition, process, and performance limitations.

What is the FDA regulatory status of decitabine?

Dacogen is FDA-approved for treatment of myelodysplastic syndromes, including previously treated and untreated de novo and secondary MDS. Inqovi is FDA-approved for treatment of adult patients with MDS, including previously treated and untreated de novo and secondary MDS with the relevant disease classifications. [1,2]

Decitabine products are regulated as small-molecule drugs. Biosimilar pathways do not apply. Follow-on products generally proceed through an abbreviated new drug application when they can demonstrate pharmaceutical equivalence and bioequivalence, or through a full or hybrid application when the dosage form, route, or clinical profile differs materially.

When does decitabine lose exclusivity?

The practical exclusivity position depends on the specific product rather than the molecule alone.

Product or protection category	Status
Decitabine active ingredient	Mature small-molecule compound
Dacogen intravenous formulation	Mature product with generic competition potential
Inqovi fixed-dose combination	Later product with combination-specific patent and regulatory considerations
Formulation improvements	May receive separate patent terms if novel and non-obvious
Method-of-use claims	May remain relevant even after composition claims expire
Orphan-drug or other regulatory exclusivity	Must be assessed by product and indication in FDA databases

The commercial loss of exclusivity for intravenous decitabine is driven by generic approval and supply economics. For Inqovi, entry risk depends on Orange Book patents, paragraph IV certifications, settlement terms, and whether a challenger can demonstrate bioequivalence for the combination tablet.

Which companies are challenging decitabine products?

Generic competition is more developed for intravenous decitabine than for oral decitabine/cedazuridine. Multiple generic manufacturers and contract manufacturers may participate in the injectable market, subject to FDA approval and commercial supply decisions.

Inqovi faces a higher technical barrier because a challenger must reproduce the combined exposure of decitabine and cedazuridine in a fixed-dose oral product. A paragraph IV challenge could target composition, dosage regimen, pharmacokinetic, or method-of-use patents listed for the product.

Publicly available FDA records and court dockets should be used to identify current ANDA applicants, patent certifications, and litigation. The existence of an ANDA filing does not establish an approved launch date.

What patent litigation and settlement issues affect decitabine?

The principal litigation risks involve:

• Paragraph IV challenges to Inqovi patents.
• Declaratory judgment actions concerning listed patents.
• Hatch-Waxman litigation triggered by notice letters.
• Settlement agreements that establish a licensed generic-entry date.
• Patent-term adjustment or pediatric-extension calculations.
• Carve-outs for method-of-use indications.
• Manufacturing-process claims asserted outside the Orange Book.

A settlement can materially change the launch timeline even when the branded product retains nominal patent coverage. The commercial analysis should distinguish between patent expiration, licensed entry, authorized generic supply, and at-risk launch.

How does decitabine compare with azacitidine?

Attribute	Decitabine	Azacitidine
Drug class	DNA methyltransferase inhibitor	DNA methyltransferase inhibitor
Intravenous availability	Yes	Yes
Subcutaneous availability	Limited or product-specific	Established for injectable azacitidine
Oral product	Decitabine/cedazuridine	Oral azacitidine has a separate product and indication profile
Main formulation issue	Aqueous instability and oral deamination	Route-specific absorption and formulation constraints
Excipient opportunity	Stability, ready-to-use injection, oral exposure	Oral delivery, injectable convenience, and dose-form differentiation
Biosimilar pathway	Not applicable	Not applicable

Decitabine’s strongest formulation opportunity is an easier-to-administer product. Azacitidine’s competitive position is stronger where subcutaneous administration is preferred, while oral decitabine/cedazuridine competes on outpatient convenience.

What generic launch scenarios exist?

Scenario 1: Injectable price erosion

Generic intravenous decitabine launches produce rapid price pressure, particularly in hospital and group-purchasing channels. Branded value shifts toward supply reliability, vial efficiency, and service.

Scenario 2: Premium ready-to-use presentation

A manufacturer launches a more stable, ready-to-administer product at a premium. Adoption depends on documented reductions in preparation time and waste.

Scenario 3: Oral combination challenge

A generic or authorized generic version of decitabine/cedazuridine enters after patent resolution. The principal commercial advantage is lower acquisition cost, but switching may be constrained by prescriber familiarity and reimbursement arrangements.

Scenario 4: Formulation-led new product

A company develops an oral or injectable formulation with a distinct pharmacokinetic profile. This may obtain new patent protection but would require a larger clinical and regulatory investment.

What geographic opportunities exist?

The United States offers the clearest patent and Orange Book pathway. European opportunities depend on national reimbursement, centralized or decentralized approvals, and local hospital procurement.

Emerging markets may favor:

• Lower-cost injectable decitabine.
• Room-temperature or extended-stability products.
• Smaller vial configurations.
• Simplified reconstitution.
• Local sterile manufacturing.
• Oral products that reduce infusion-center demand.

Manufacturing localization may create competitive advantage where imported sterile products face supply interruptions, registration delays, or cold-chain constraints.

Key Takeaways

• Decitabine’s main formulation problem is aqueous instability, not excipient complexity.
• Lyophilized intravenous decitabine remains the lowest-risk commercial platform.
• The most practical injectable opportunities are longer in-use stability, reduced reconstitution burden, improved vial economics, and ready-to-administer packaging.
• Oral decitabine is technically more difficult because cedazuridine addresses first-pass deamination through a mechanism that excipients alone may not replicate.
• Inqovi is the key product for combination, method-of-use, pharmacokinetic, and formulation patent analysis.
• Decitabine is a small-molecule drug and has no biosimilar pathway.
• Generic competition is more immediate for intravenous decitabine than for oral decitabine/cedazuridine.
• Strong formulation patents should connect excipient composition to measurable stability, bioavailability, dissolution, or handling improvements.
• The highest-value commercial position is a product that reduces pharmacy labor or improves outpatient treatment without introducing substantial cold-chain or manufacturing cost.

FAQs

Can decitabine be formulated as a ready-to-use injection?

Potentially, but chemical stability in aqueous solution is the primary barrier. A successful product would need extended stability, acceptable degradation limits, container compatibility, sterility, and a commercially viable manufacturing process.

Which excipient is most important in intravenous decitabine?

The buffer and pH-control system is central because pH affects decitabine stability. The lyophilization cycle and container closure are equally important to final product performance.

Can an excipient replace cedazuridine in oral decitabine?

An excipient may improve dissolution or absorption, but it does not necessarily replace inhibition of cytidine deaminase. A replacement product would need clinical evidence showing comparable or superior systemic exposure.

Is there a biosimilar opportunity for decitabine?

No. Decitabine is a chemically synthesized small molecule. Follow-on competition uses generic-drug or new-drug pathways rather than the biosimilar pathway.

What is the best commercial entry point for a formulation company?

The most accessible entry point is an improved sterile injectable platform focused on stability, reconstitution, packaging, or ready-to-administer delivery. Oral decitabine offers greater differentiation but requires stronger pharmacokinetic and clinical evidence.

References

1. U.S. Food and Drug Administration. (2023). Dacogen (decitabine) for injection prescribing information.
2. U.S. Food and Drug Administration. (2023). Inqovi (decitabine and cedazuridine) tablets prescribing information.
3. National Cancer Institute. (n.d.). Decitabine: Drug information and clinical use.
4. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book.